By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it received Health Canada approval of the cancer drug Imbruvica in combination with obinutuzumab for treatment-naive patients with active chronic lymphocytic leukemia, or CLL.

Janssen said the indication marks the first approval for a non-chemotherapy combination regimen for treatment-naive patients with CLL, one of the most common types of leukemia in adults.

It also marks the ninth indication for Imbruvica in Canada since its first approval in November 2014, Janssen said.

Imbruvica is commercialized in Canada by Janssen, which jointly develops the drug with AbbVie Inc.'s (ABBV) Pharmacyclics LLC.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 08, 2019 09:02 ET (14:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.